New analysis to be offered at this yr’s European Congress on Weight problems (Venice, Italy, Could 12-15) exhibits that the weight problems medicine tirzepatide persistently reduces body weight and waist circumference whatever the size of time the particular person has been residing with obese or weight problems. The research is by Dr Giovanna Muscogiuri, College of Naples Federico II, Naples, Italy, and colleagues.
Tirzepatide (Mounjaro®) was authorised by the US Meals and Drug administration (FDA) and the European Medicines Company (EMA) for the remedy of sort 2 diabetes in 2022. In November 2023, the FDA authorised tirzepatide (Zepbound®) for power weight administration in adults with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with at the very least one weight-related comorbidity. Additionally in November 2023, the EMA Committee for Medicinal Merchandise for Human Use supplied a optimistic opinion on extension of the Mounjaro® label to incorporate weight administration in adults with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and at the very least one weight-related comorbid situation.
The SURMOUNT part 3 trials evaluated tirzepatide versus placebo in individuals with weight problems or obese with at the very least 1 weight-related comorbidity with out sort 2 diabetes (SURMOUNT-1, 72 weeks), with sort 2 diabetes (SURMOUNT-2, 72 weeks), and with out sort 2 diabetes after a 12-week intensive life-style intervention (SURMOUNT-3, 72 weeks from randomization) or after a 36-week open label tirzepatide lead-in (SURMOUNT-4, 52 weeks from randomization).
On this subgroup evaluation, individuals in every research have been grouped primarily based on obese/weight problems illness period at baseline (10 years or much less, between 10 and 20 years, and above 20 years, decided by affected person report). Proportion body weight change, the proportions attaining weight reduction targets of 5, 10, 15, 20, and 25%, and the change in waist circumference have been analyzed.
Contributors randomized to tirzepatide achieved higher weight reductions in comparison with placebo at research endpoint whatever the period of illness. This was constant throughout the totally different SURMOUNT research, and the magnitude of discount was typically related throughout the illness period classes. Typically, extra tirzepatide-treated individuals achieved the load discount targets of 5, 10, 15, 20, and 25% in contrast with placebo-treated individuals, no matter illness period. Tirzepatide decreased waist circumference to a higher extent than placebo for every illness period class in SURMOUNT-1 to -4 (see desk in full summary). These reductions have been constant throughout illness period subgroups.
For instance, within the SURMOUNT-1 trial, for sufferers given 10mg dose of tirzepatide, these with illness period beneath 10 years misplaced 21% of their weight after 72 weeks, in comparison with 20% physique weight reduction for these with 10-20 years illness period and 23% for these with over 20 years illness period. Within the SURMOUNT-2 trial (the place all individuals have been additionally residing with sort 2 diabetes), for sufferers given the 15mg dose of tirzepatide, these with illness period beneath 10 years misplaced 13% of their body weight, in contrast with 16% in these with illness period of 10-20 years and 17% body weight loss for these residing with obese or weight problems for over 20 years. Waist circumference reductions adopted related traits (see desk full summary).
The authors conclude: “Tirzepatide persistently decreased physique weight and waist circumference in individuals residing with weight problems or obese with weight-related comorbidities whatever the period of illness. These outcomes are in keeping with the general findings from every research within the SURMOUNT program.”
Supply:
European Congress on Weight problems
